Eμ-TCL1 mice with conditional human BCL2 knock-in as novel B cell lymphoma model for studying venetoclax effects in vivo Open Access

1University of Cologne, Faculty of Medicine and Cologne University Hospital, Department I of Internal Medicine; Center for Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf; Cologne, Germany

2CECAD Cologne Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases; Cologne, Germany

3Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Salzburg, Austria; Salzburg Cancer Research Institute and Cancer Cluster Salzburg, Austria

1University of Cologne, Faculty of Medicine and Cologne University Hospital, Department I of Internal Medicine; Center for Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf; Cologne, Germany

2CECAD Cologne Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases; Cologne, Germany

5Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University Duisburg-Essen, Germany

5Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University Duisburg-Essen, Germany

2CECAD Cologne Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases; Cologne, Germany

4University of Cologne, Faculty of Medicine and Cologne University Hospital, Institute for Molecular Immunology, Cologne, Germany

6Faculty of Medicine and University Hospital of Cologne, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne Germany

1University of Cologne, Faculty of Medicine and Cologne University Hospital, Department I of Internal Medicine; Center for Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf; Cologne, Germany

2CECAD Cologne Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases; Cologne, Germany

6Faculty of Medicine and University Hospital of Cologne, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne Germany

7Department of Hematology, Oncology and Tumor Immunology, Charité, Campus Benjamin Franklin, University Medicine Berlin, Berlin, Germany

7Department of Hematology, Oncology and Tumor Immunology, Charité, Campus Benjamin Franklin, University Medicine Berlin, Berlin, Germany

3Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Salzburg, Austria; Salzburg Cancer Research Institute and Cancer Cluster Salzburg, Austria

1University of Cologne, Faculty of Medicine and Cologne University Hospital, Department I of Internal Medicine; Center for Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf; Cologne, Germany

2CECAD Cologne Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases; Cologne, Germany

1University of Cologne, Faculty of Medicine and Cologne University Hospital, Department I of Internal Medicine; Center for Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf; Cologne, Germany

2CECAD Cologne Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases; Cologne, Germany

1University of Cologne, Faculty of Medicine and Cologne University Hospital, Department I of Internal Medicine; Center for Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf; Cologne, Germany

2CECAD Cologne Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases; Cologne, Germany

6Faculty of Medicine and University Hospital of Cologne, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne Germany